A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.
Summary
The goal of this trial is to learn if drugs in group A, B, C and D works to treat reversal of grades in people with overt hepatic encephalopathy. It will also provide information regarding safety of drugs in group A, B, C and D. The main question it aim to answer is: Which study group is better in treating people of overt hepatic encephalopathy. Researchers will compare experimental group B (rifaximin + lactulose), group C (probiotics + lactulose) and group D (LOLA (L-Ornithine L-Aspartate) + lactulose) to control group A lactulose alone in the reversal of grades for people of hepatic encephalopathy. Participants will: Take drug from time of participation in the trial till the end of treatment (day 5) and grade reversal will be observed.
Timeline
- Start
- 2024-12-02
- Primary completion
- 2025-04-21
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-ornithine L-aspartate | Other / unclassified | 20 g | Intravenous |
| Comparator | Lactulose | Other / unclassified | 30 ml | Oral |
| Subject | Probiotic plus lactulose | Unknown | 2 g | Oral |
| Subject | Rifaximin | Other / unclassified | 550 mg | Oral |